Proximity-confined DNA walking-nanozyme cascades for multiplexed urinary extracellular vesicle phenotyping and machine learning-assisted disease stratification.
A urine test using engineered particles can detect cancer signatures with high accuracy, suggesting a noninvasive screening approach for prostate cancer.
Proximity-confined nanozyme biosensing platform achieves ultrasensitive multiplexed urinary EV phenotyping (CD63/EGFR/PAK6, detection limits 1.7-4.3x10^4 particles/mL) with 91% multiclass accuracy distinguishing healthy, diabetes, and prostate cancer from clinical urine samples using ML. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- technical_development_proof_of_concept
- Category
- early_cancer_detection
- Maturity
- Exploratory
- Journal
- Biosensors and Bioelectronics
Why it surfaced
Highly innovative biosensing architecture; non-invasive urine-based platform combining nanomaterial signal amplification with ML for multi-disease stratification; relevant to both T3 (liquid biopsy) and T4 (AI/ML diagnostics) watchlists; Biosensors and Bioelectronics is the top journal in this space.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.